Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for HIV Pre-Exposure Prophylaxis (PrEP): A Pooled Observational Study

First published 12/07/2018

Last updated 23/04/2024

EU PAS number:

EUPAS24332

Study

Finalised

Documents

Study protocol

Initial protocol

protocol GS-US-276-0104_f-redact

English (447.12 KB - PDF)View document

Study results

GS-US-276-0104-csr-final_f-redact

English (2.27 MB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs